← All trials
NCT03822013
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2019
- Primary completion
- Jan 14, 2020
- Completion date
- Jan 14, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TehranLead sponsor
- University of TehranReponsible party - principal investigator
- Mashhad University of Medical SciencesCollaborator
- Kashan University of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.